Korro reports first quarter 2025 financial results and provides business updates

Cambridge, mass., may 07, 2025 (globe newswire) -- korro bio, inc. (korro) (nasdaq: krro), a clinical-stage biopharmaceutical company focused on developing a new class of genetic medicines based on editing rna for both rare and highly prevalent diseases, today reported financial results for the first quarter of 2025 and provided a business update.
KRRO Ratings Summary
KRRO Quant Ranking